Theoretical stack · Performance & Muscle

Hypertrophy & Anabolic Performance Stack

IGF-1 LR3 + MGF + Follistatin-344 + Hexarelin

Low (research-only / WADA-banned)

Theoretical educational discussion

This page summarizes a peptide combination as discussed in the research and user communities. It does not constitute medical advice, dosing recommendations, or instructions for personal use. Combination-specific human RCT evidence is generally absent for these stacks; per-compound evidence does not transfer additively to combinations.

Decisions about peptide therapy require an appropriately licensed clinician. We do not sell peptides.

At a glance

The most-discussed direct-anabolic peptide combination in the bodybuilding research community — distinct from GH-secretagogue stacks like CJC/Ipamorelin in that it pairs direct IGF-1 supply with myostatin-pathway suppression. Heavy WADA-banned and grey-market regulatory considerations.

Compounds in the stack

Each compound's role in the combination, with link to its full peptide page for the underlying research.

IGF-1 LR3

Long Arg3 IGF-1 — the long-acting research-grade IGF-1 analog; provides direct anabolic IGF-1 receptor signaling without going through GH/IGF-1 axis

Half-life: ~20 hours · Research-grade only

MGF

Mechano growth factor — locally produced IGF-1 splice variant active in damaged skeletal muscle; community use targets specific muscle groups

Half-life: minutes · Research-grade only

Follistatin 344

Myostatin and activin pathway antagonist; relieves the suppressive arm of muscle growth signaling

Research-grade only · WADA-banned

Hexarelin

Older potent ghrelin-mimetic GH secretagogue with documented cardiovascular preclinical effects beyond the GH axis

Research-grade only · Less selective than ipamorelin

Mechanistic rationale

This stack represents the more aggressive end of community peptide use — direct IGF-1 receptor signaling (IGF-1 LR3 and MGF), myostatin-pathway suppression (Follistatin-344), and GH-secretagogue stimulation (Hexarelin) combined to maximize anabolic signaling across multiple parallel pathways.

The pharmacologic logic is clean: rather than working only through the endogenous GH/IGF-1 axis (the CJC-1295 + Ipamorelin route), this stack adds direct IGF-1 supply (IGF-1 LR3), local muscle-tissue IGF-1 signaling (MGF), and removes the myostatin-pathway brake on hypertrophy (Follistatin-344). The combination engages substantially more of the anabolic signaling network simultaneously than any single-mechanism approach.

The honest framing: this is the framework most associated with serious-enthusiast and competitive bodybuilding-context use rather than mainstream peptide-research discussion. The corresponding regulatory, safety, and athletic-prohibition considerations are substantial.

Human and emerging evidence

The peer-reviewed literature on this combination is summarized below across two tiers — controlled human research (the highest standard) and preclinical / animal-model evidence.

Reported user experiences

The reports below are aggregated from research forums, podcasts, and user-community discussions. They are useful as hypothesis-generating signals but are not controlled clinical data — selection bias, placebo response, and underreporting of adverse effects all apply.

Discussion is concentrated in advanced bodybuilding and serious-enthusiast peptide communities. Reports describe more rapid muscle gain than seen with GH-secretagogue stacks alone, alongside more pronounced side-effect profiles (hypoglycemia from IGF-1, water retention, increased fasting glucose with chronic use). Selection bias is substantial — users in these communities are typically also using other anabolic strategies, making the contribution of this peptide stack specifically difficult to isolate.

Potential benefits and risks

Potential benefits

Most aggressive pharmacologic anabolic stack discussed in the peptide-research community
Engages multiple parallel anabolic signaling pathways simultaneously
Mechanistic rationale is well-supported at the preclinical level
Documented effects on muscle protein synthesis biomarkers

Potential risks

All four components are research-grade only; none are FDA-approved for hypertrophy or performance use
WADA-banned; users in any tested-athlete context will fail anti-doping protocols
Hypoglycemia risk from IGF-1 is real and dose-dependent
Sustained IGF-1 elevation is epidemiologically associated with elevated cancer risk; long-term use safety is uncharacterized
Cardiac hypertrophy risk from sustained IGF-1/follistatin-pathway activation is a theoretical concern not fully evaluated in long-term human use
Source quality in research-peptide markets varies widely; identity and purity assurance is a real concern
Combination-specific safety data does not exist

Open questions

What is the long-term cancer-risk profile of sustained multi-pathway anabolic peptide use?
Does follistatin-344 supplementation produce cardiac hypertrophy at meaningful rates in human use?
How do these combinations interact with anabolic steroid protocols typical in the same user population?
Is there any evidence-based path to validate (or rule out) the long-term use patterns prevalent in bodybuilding communities?

The takeaway

The Hypertrophy & Anabolic Performance stack is the most aggressive peptide combination on the site and the one most disconnected from clinical evidence-based medicine. The mechanistic logic is internally coherent, but the safety profile is substantially less characterized than other stacks here, and the use context (advanced bodybuilding) introduces additional confounders that make user-report data particularly difficult to interpret. For users considering this framework, the appropriate read is: this is community pharmacology rather than clinical practice, the regulatory and athletic-prohibition implications are serious, and the long-term safety profile of sustained multi-pathway anabolic peptide use is not characterized in any rigorous human dataset. Most users would be better served by the GH-secretagogue stack (CJC + Ipamorelin) at far lower risk.

References

Goldspink G. Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology (Bethesda). 2005;20:232-238. https://pubmed.ncbi.nlm.nih.gov/16024511/
Lee SJ. Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction. J Clin Invest. 2021;131(9):e148372. https://pubmed.ncbi.nlm.nih.gov/33938454/
Imboden MT, et al. Insulin-like growth factor-1 and risk of all-cause and cancer-specific mortality. J Clin Endocrinol Metab. 2022;107(5):e1973-e1985. https://pubmed.ncbi.nlm.nih.gov/?term=IGF-1+cancer+mortality
Locatelli V, Bianchi VE. Effect of GH/IGF-1 on bone metabolism and osteoporosis. Int J Endocrinol. 2014;2014:235060. https://pubmed.ncbi.nlm.nih.gov/25147494/